The unit, in Alliance Park Braine l'Alleud, south of Brussels, Belgium, will act as Baxter’s hub for development of recombinant, plasma-based therapeutics, vaccines, packaging and delivery systems and peritoneal dialysis devices.
Baxter has operated in Belgium for fifty years, previously basing its R&D operations in Nivelles and the capital Brussels. However, according to company vice president Ludwig Hantson, the new unit offers a number of advantages.
“Alliance Park provides a critical step forward in Baxter's future by aligning multiple functions in one area, thereby encouraging more ideas to develop into solutions that serve healthcare professionals and patients."